BCLSI
Bain Capital Life Sciences Investors Portfolio holdings
AUM
$799M
1-Year Return
36.47%
This Quarter Return
+50.78%
1 Year Return
+36.47%
3 Year Return
+278.05%
5 Year Return
+363.53%
10 Year Return
–
AUM
$1.24B
AUM Growth
+$201M
(+19%)
Cap. Flow
-$23.1M
Cap. Flow
% of AUM
-1.86%
Top 10 Holdings %
Top 10 Hldgs %
81.83%
Holding
29
New
2
Increased
3
Reduced
11
Closed
3
Top Buys
| 1 |
Dianthus Therapeutics
DNTH
|
+$89.8M |
| 2 |
Kyverna Therapeutics
KYTX
|
+$78.6M |
| 3 |
Solid Biosciences
SLDB
|
+$12M |
| 4 |
Annexon
ANNX
|
+$4.6M |
| 5 |
Savara
SVRA
|
+$1.66M |
Top Sells
| 1 |
Nuvalent
NUVL
|
+$66.1M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
+$34.1M |
| 3 |
Revolution Medicines
RVMD
|
+$31.9M |
| 4 |
Natera
NTRA
|
+$25.1M |
| 5 |
Pharvaris
PHVS
|
+$13.9M |
Sector Composition
| 1 | Healthcare | 98.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
NewAmsterdam Pharma Company N.V. Warrant
NAMSW
$62.3M
| $1.1M | 0.09% |
100,000
| – | – |
|
|
27
Natera
NTRA
$23.1B
| – | – |
-400,197
| Closed | -$25.1M |
|
|
28
Revolution Medicines
RVMD
$8.7B
| – | – |
-1,112,396
| Closed | -$31.9M |
|
|
TSVT
29
DELISTED
2seventy bio
TSVT
| – | – |
-1,331,801
| Closed | -$5.69M |
|